ZYME (US) share price forecast & AI signal — Zymeworks Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in ZYME
Zymeworks Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Zymeworks Inc
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $29.63 |
| 2026-11-05 | $28.73 |
| 2026-11-04 | $30.94 |
| 2026-11-03 | $30.13 |
| 2026-11-02 | $28.99 |
| 2026-10-30 | $28.61 |
| 2026-10-29 | $28.71 |
ZYME FAQ
Is Zymeworks Inc (ZYME) a buy or sell this week?
The ACE Stock Bots machine-learning model rates ZYME a BUY for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for ZYME?
Every week the model scores ZYME across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.